Search Results

David Sykes About Dr. David Sykes " David Andrew Sykes, BSc Hons Pharmacology, MSc Molecular Biology and Biochemistry, PhD David has over 20+ years of experience working in a drug discovery environment mainly in a specialist In 2014 David joined the University of Nottingham and began a part-time PhD in Molecular Pharmacology David Sykes on the web Veprintsev Lab ResearchGate LinkedIn Dr. GPCR Unlock the Full Dr.

Davide Calebiro About Dr. Davide Calebiro "Davide Calebiro is Chair of Molecular Endocrinology and Wellcome Trust Senior Research Davide’s work has been published in prestigious scientific journals such as Nature, Cell, New England Davide Calebiro on the web University of Birmingham Twitter Google Scholar LinkedIn Dr.

. << Back to podcast list Strategic Partner(s) David Gloriam: Orphan Receptors, GPCRDB, and the Data intersection of computational biology, cheminformatics, and structural pharmacology through the work of David ABOUT THE GUEST David Gloriam is a professor at the University of Copenhagen's Department of Drug Design Verify against the published audio before use. 00:00 Welcome and introduction of David Gloriam 02:23 Join me a learn more about David’s work, his career trajectory, and GPCRdb. Dr. David E.

Lauren M. Slosky About Dr. Lauren M. Lauren M.

David Hodson on visualizing GLP-1 and GIP receptors in pancreatic islets and brain circuits to advance Strategic Partner(s) Visualizing GLP-1 & GIP Receptors in Islets and Brain In this episode, Professor David About David Hodson Prof. David Hodson is the Robert Turner Professor of Diabetic Medicine at the University of Oxford , working David Hodson on the Web Radcliffe Department of Medicine Islet Biology Lab University of Birmingham Unlock

conversation are Maria Majellaro (CSO and co-founder of Celtarys Research), Johannes Broichhagen, and David fluorescence-based probe design, and how functional assay development benefits from scalable distribution rather than David Hodson, PhD Dr. David Hodson is the Robert Turner Professor of Diabetic Medicine at the University of Oxford and a leading LinkedIn Google Scholar Lab Website Leibniz Research Institute for Molecular Pharmacology (FMP) Profile David

Psychiatry GPCR drug targets carry genetic variation that is far more widespread across human populations than He completed his PhD under David Gloriam in Copenhagen and an external stay at the MRC Laboratory of Orphan receptors can be systematically approached through evolutionary logic Rather than screening compound science 13:06 - First exposure to computational chemistry - a rotation in Hyderabad 16:04 - Joining David During his Ph.D. with David Gloriam at the Department of Drug Design and Pharmacology in Copenhagen,

Gáspár Pándy-Szekeres " After a BSc in biology and a MSc in bioinformatics, I have been working in David

Lukas Grätz "After a BSc in biology and a MSc in bioinformatics, I have been working in David Gloriam's

Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure

David Sibley (1988) Memories our panelists shared with us https://video.wixstatic.com/video/93ce84_92e3a06139244357b0823e3ecc294e27

How collaborations with David Parker and Jean-Philippe Pin accelerated both probe chemistry and biological

David Hodson Robert Turner Professor of Diabetic Medicine Oxford Centre for Diabetes, Endocrinology and Takes less than a minute to join. Cancel anytime. Sign Up for Free

, application-specific testing VirDTM-GPCR arrays for cross-reactivity screening when feasible More than and ligand-dependent conformations How to design functional assay panels that quantify bias rather than David Hodson Topics Covered: LUXendin probes for GLP-1R labeling across imaging modalities daLUXendin They're designed for scientists who want deep, data-driven discussion rather than surface-level overviews

Biased agonism is in a harder place than the field often acknowledges. Graduate student David Duran wanted to test intermittent fasting in mice. Dr. argues the field's default assumption — pick a low-expression, tissue-restricted target — is more habit than

David Tuveson at CSHL where he participated in the development of an organoid system for the culture

Kathleen Caron About Kathleen M. Caron Kathleen M. Caron, Ph.D. is the Frederik L. Kathleen M. Caron on the web Lab Website Twitter Pubmed Google Scholar Orcid Unlock the Full Dr.

mechanisms of flavonoids in cancer using nuclear magnetic resonance spectroscopy (NMR) led to a Barry M.

Founder & Director Yamina Berchiche Get in touch Co-Founder Attila Foris Get in touch Board Member Anne M.

I spent time running for the chair of International Affairs for the U-M Postdoctoral Association (UMPDA

Kathleen Caron " "Kathleen M. Caron, Ph.D. is the Frederik L.

Journey Today Meet the Leadership Founder & Director Yamina Berchiche Get in Touch Board Member Anne M.

Ben M Clements is a behavioral pharmacologist who uses in vitro and in vivo models to discover and characterize